Clinical trials: Diffuse Diabetic Macular Edema
Diffuse Diabetic Macular Edema
Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
Diffuse Macular Edema is the main cause of visual disorders in diabetic patients. Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse…
- Trial name
- NCT00999791
- Testing
- Bevacizumab, Diclofenac
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Macular Edema
Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser
This study compares the use of intravitreous triamcinolone and laser therapy to treat maculopahty in patients with type 2 diabetes mellitus in a short-tem period of 6 months
- Trial name
- NCT00668239
- Testing
- intravitreous triamcinolone, laser therapy
- Where
- 3 sites in Brazil
- Volunteers
- 14 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Diabetic Macular Edema
Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema
Macular edema constitutes the primary cause of visual impairment in diabetic patients with a disease duration of 20 years or more.
- Trial name
- NCT00371410
- Testing
- vitrectomy, intravitreal triamcinolone acetonide, macular focal laser photocoagulation
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Diabetes Mellitus, Macular Edema
Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema
The purpose of this study is to determine whether intravitreal injection of Triamcinolone Acetonide is effective in the treatment of Clinically Significant Diffuse Macular Edema due to Type 2 Diabetes Mellitus.
- Trial name
- NCT00309192
- Testing
- Triamcinolone Acetonide, Grid laser
- Where
- 7 sites in Spain
- Volunteers
- 292 people
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Diffuse Diabetic Macular Edema
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.
- Trial name
- NCT00886808
- Testing
- iCo-007 Intravitreal Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- iCo Therapeutics Inc.
Diffuse Diabetic Macular Edema
Triple Therapy for Diffuse Diabetic Macular Edema
The purpose of this study is to evaluate the safety end efficacy of combined phakoemulsification and vitrectomy with retinal endophotocoagulation and intraoperative use of bevacizumab in patients with diffuse diabetic macular…
- Trial name
- TTDDME (NCT01218750)
- Testing
- Triple therapy for diffuse diabetic macular edema
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Military Institute od Medicine National Research Institute
Diffuse Diabetic Macular Edema
Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema
To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.
- Trial name
- NCT00571142
- Testing
- Bevacizumab + Pars plana vitrectomy
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetes Mellitus Type 2, Diabetic Macular Edema
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema
- Trial name
- NCT00417716
- Testing
- Intravitreal Bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetic Retinopathy
Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema
Phase I/II study with intravitreal triamcinolone acetonide microspheres(RETAAC)for treatment of diffuse diabetic macular edema unresponsive to laser photocoagulation.
- Trial name
- NCT00407849
- Testing
- triamcinolone acetonide
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Federal University of São Paulo
Diffuse Diabetic Macular Edema
POSTERIOR SUB-TENON'S Avastin
Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema
- Trial name
- NCT00567372
- Testing
- bevacizumab (Sub-tenon´s injection)
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetes Mellitus, Diabetic Retinopathy
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
This study will evaluate the safety and efficacy of AG-014699 in diabetic patients
- Trial name
- NCT00457470
- Testing
- AG-014699
- Sponsor
- Pfizer
Diabetic Macular Edema
Grid Laser for Diffuse Diabetic Maculopathy
Diabetic related complications are increasing day by day due to increse in the number of diabetic patients all over the world. Diabetic macular edema is one of them and a major cause of vision imparment.
- Trial name
- MMG (NCT02555956)
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Dow University of Health Sciences
Diffuse Diabetic Macular Edema
Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study
Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema.
- Trial name
- NCT00600301
- Testing
- Triamcinolone Acetonide and Bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetic Macular Edema
Topcon Endpoint Management
This trial seeks to prove that sub-lethal laser power levels are as effective and less damaging than traditional laser. Diabetic macular edema (DME) affects approximately 29% of diabetic patients with a disease duration of 20 or…
- Trial name
- Topcon EM (NCT01732614)
- Testing
- Topcon Endpoint Management laser
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Retinal Consultants of Arizona
Diabetic Macular Edema
Micropulse 810 Nanomolar (nm), Diode Laser for Diffuse Diabetic Macular Edema
Objective: To compare micropulse 810nm diode laser photocoagulation versus argon laser photocoagulation for treatment of diabetic macular edema.
- Trial name
- NCT00552435
- Testing
- Laser photocoagulation
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Federal University of São Paulo
Diabetic Macular Edema
Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema
This clinical trial is designed to investigate differences in terms of efficacy (mean change in best corrected visual acuity obtained after 12 months of treatment) and safety, of 3 therapeutic estrategies for non-tractional…
- Trial name
- ALBA (NCT01572350)
- Testing
- Grid laser, Triamcinolone Acetonide, Bevacizumab
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- Hospital Universitario de Canarias
Diabetic Macular Edema
Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
This is an investigator-sponsored trial (IST), an open-label pilot study, assessing the safety and biologic activity of bromfenac in subjects with diffuse DME refractory to laser.
- Trial name
- NCT00491166
- Testing
- Bromfenac ophthalmic solution
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ophthalmic Consultants of Boston
Diabetic Macular Oedema
Sub-threshold Photocoagulation of Diabetic Macular Oedema
Topcon's Endpoint Management (EM) is a new software from the Pascal® laser which allows us to decrease the intensity of the burns (invisible burns) showing some landmarks with normal intensity so the investigators can see the…
- Trial name
- MEM (NCT02309476)
- Testing
- PASCAL Laser, Green Laser 0.75, PASCAL Laser, Green Laser 1, PASCAL Laser, 70% Yellow Laser 0.75
- Where
- United Kingdom
- Sponsor
- Manchester University NHS Foundation Trust